Last reviewed · How we verify

NCT06749847: MIRABELLE

HPV Self-sampling in the General Population

Recruiting now NA Last updated 23 July 2025
What this trial tests

NA trial testing Women receive invitation letter with HPV self-sampling kit in Cervical Cancer in 6,000 participants. Currently enrolling.

Timeline
26 June 2025
Primary endpoint
30 June 2026
31 December 2026

Quick facts

Lead sponsorInternational Agency for Research on Cancer
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposescreening
Enrollment6,000
Start date26 June 2025
Primary completion30 June 2026
Estimated completion31 December 2026
Sites2 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

International Agency for Research on Cancer

Who can join

Adults 30 to 65, female only, with Cervical Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A randomized controlled trial comparing three strategies for cervical cancer screening: direct mailing of HPV self-sampling kit ("Outreach" arm), choice between self-sampling or healthcare provider sampling ("Choice" arm), and standard care (control arm) in two French departments.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cervical Cancer

Currently open trials in the same condition.

Other International Agency for Research on Cancer trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06749847.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing